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Deficiencies in the activity of specific pathways for serot-
onin (5-HT, 5-hydroxytryptamine), and norepinephrine
(NE) have long been hypothesized to account for the
symptoms of major depressive disorder (MDD). More
than 30 years ago, it was noted that pharmacological
agents that enhance the availability of the monoamine
neurotransmitters serotonin, norepinephrine, and
dopamine, produced a clinically meaningful improve-
ment in mood in patients suffering from MDD. This clin-
ical observation led to the development of the so-called
'monoamine hypothesis' of depression, which proposed
that functional disruptions in these neurotransmitter sys-
tems mediate the behavioural and physiological symp-
toms (e.g. painful physical symptoms) of depression and
related conditions. The pharmacotherapy of MDD has
relied principally on the development of agents that alter
or increase the functional activity of these classical neuro-
transmitter systems [1].
A major disadvantage of the older drugs, such as the clas-
sic tricyclic antidepressants (TCAs), is their safety profile.
Adverse events resulting from the use of such drugs are fre-
quently reported by patients as a reason for stopping treat-
ment. Newer agents, acting primarily only on one
neurotransmitter system, such as the selective serotonin
reuptake inhibitors (SSRI) are generally accepted to be
effective antidepressants with a favourable side-effect pro-
file relative to many of the older drugs. However, only
approximately 30% of patients may be expected to
achieve remission of illness with SSRI monotherapy.
Recent clinical evidence has accumulated that the selective
enhancement of both 5-HT and NE systems provide a
more robust clinical effect, e.g., in terms of higher remis-
sion rates [1].
Duloxetine hydrochloride is a novel, balanced and potent
dual reuptake inhibitor of both 5-HT and NE. Duloxet-
ine's efficacy in the treatment of major depression has
been established in a series of placebo-and comparator-
controlled trials, and offers consistent efficacy on both the
emotional and painful physical symptoms of depression,
together with good tolerability and ease of use [2]. Data
indicate that duloxetine is an important addition to the
existing treatment options for MDD because it treats the
complete depressive condition, thus allowing more
patients to not only attain, but also sustain, a state of
remission – the ultimate goal of acute depression treat-
ment.
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